United States · 
Who invested in Pheast Therapeutics?
Pheast Therapeutics's investors include ARCH Venture Partners, Alexandria Venture Investments and Catalio Capital Management.
United States · Series A startup
Who invested in Pheast Therapeutics
One round we have observed, with the 3 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.
Follow Pheast Therapeutics and see its new rounds in your feed.Start following
Funding summaryUpdated 27 Oct 2026
$76Mraised across 1 round since 2022, from 1 source
- Latest round
- Series A, $76MApr 2022
- Investors
- 3
The rounds
- Apr 2022Series A$76M
Source recorded
Founders and team
From Pheast Therapeutics's own website: 12 on the team.
- Roy MauteCofounder & Chief Executive Officer
- Susan LuebbeVice President, Clinical Operations
- Thomas MartyVice President, Finance
- Raphaël RousseauChief Medical Officer
- Giovanni ForcinaSenior Scientist I, Translational Science
- Jacob VogelsteinBoard Director
- Jen CaoSenior Director, Translational Science
- Karmen PantojaSenior Associate, Operations
- Kelsey HartAssociate Scientist, Translational Science
- Ken DinyarianManager, Information Technology
- Steve GillisBoard Director
- Tiffany van LondenAssociate Director, Business Operations
AdvisersAmira BarkalIrv WeissmanRavi Majeti
Everyone who backed them
Alexandria Venture InvestmentsVC firm1round
Missing a round, or an investor who was in one? Tell us.
Quick answers about Pheast Therapeutics
How much has Pheast Therapeutics raised?
Pheast Therapeutics has raised $76M across 1 round since 2022.
When did Pheast Therapeutics last raise?
Pheast Therapeutics's most recent round was a Series A of $76M in Apr 2022.
What was Pheast Therapeutics's biggest round?
Its most recent round, $76M in Apr 2022, is also its largest on record.
Who backed Pheast Therapeutics first?
Pheast Therapeutics's first round on record, in Apr 2022, was backed by ARCH Venture Partners, Alexandria Venture Investments and Catalio Capital Management.
What stage is Pheast Therapeutics at?
Pheast Therapeutics's latest named round is a Series A, in Apr 2022.
Where is Pheast Therapeutics based?
Pheast Therapeutics is based in the United States.
Companies like Pheast Therapeutics
In the same sector, and raised in the last eighteen months.
Find investors like these
Search every investor by what they have actually funded, then narrow to your stage and market. Free.